Ezetimibe and Simvastatin in Dyslipidemia of Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00157482|
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : February 13, 2007
Diabetes mellitus is becoming a global epidemic burden. Its chronic cardiovascular complications, myocardial infarction and stroke, are the main causes of death in diabetic patients. It was found that low density lipoprotein (LDL) cholesterol concentration is related to the increased coronary disease risk that could be successfully reduced by cholesterol-lowering therapy. Furthermore, preliminary evidence suggests that ameliorating dyslipidemia may be renoprotective in diabetic patients with proteinuria.
Ezetimibe is the first selective inhibitor of cholesterol absorption and it has demonstrated a high efficacy in lowering cholesterol concentration and an excellent safety profile. Preliminary data suggest that ezetimibe, combined with a drug that blocks the cholesterol synthesis (statins), could be even more effective in decreasing cholesterol concentration. The aim of this study is to evaluate whether ezetimibe-simvastatin combined therapy is superior to simvastatin monotherapy in ameliorating the lipid profile and albuminuria in type 2 diabetic patients.
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes||Drug: Ezetimibe Drug: Simvastatin||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||108 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Prospective, Double-Blind Study to Evaluate the Effects on Lipid Profile of Combined Ezetimibe and Simvastatin Therapy as Compared to Simvastatin Alone in People With Type 2 Diabetes|
|Study Start Date :||January 2005|
|Study Completion Date :||December 2006|
- LDL-cholesterol, at 16 weeks of treatment. LDL-cholesterol is measured at -4, 0, 8, 12 and 16 weeks.
- Total cholesterol, apolipoprotein A1 and B, lipoprotein and triglycerides, at -4, 0, 8, 12 and 16 weeks
- Urinary albumin excretion, at -4, 0, 8 and 16 weeks
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00157482
|ASl of Ponte San Pietro - Diabetologic Unit|
|Ponte San Pietro, Bergamo, Italy, 24036|
|Clinical Research Center for Rare Diseases|
|Ranica, Bergamo, Italy, 24020|
|Hospital "Treviglio Caravaggio " - Diabetologic Unit|
|Treviglio, Bergamo, Italy, 24047|
|Hospital "Ospedali Riuniti di Bergamo" - Diabetologic Unit|
|Bergamo, Italy, 24128|
|Principal Investigator:||Piero Ruggenenti, MD||Mario Negri Institute|